Proactive Investors - Run By Investors For Investors

Orgenesis teams up with HemoGenyx in second collaboration to push cancer cell replacement product to clinical trials

In part two of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx Pharmaceuticals Plc (LON:HEMO), CEO Vered Caplan of Orgenesis and CEO Vladislav Sandler of HemoGenyx tell Proactive Investors the two biopharmas will work together yet again on HemoGenyx’s Human Postnatal Hemogenic Endothelial Cell (Hu-PHEC) technology.

Hu-PHEC is a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.

As with the first agreement, Orgenesis will invest at least another $1million in HemoGenyx through a convertible loan, which can be converted into either HemoGenyx or Orgenesis stock.

View full ORGS profile View Profile

Orgenesis Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use